OmniComm Launches TrialOne Express
Early stage researchers, including Phase I Clinics and Units, with limited resources now have access to a new eClinical research option designed to accelerate and enhance clinical operations. OmniComm Systems, Inc. (OTCQX: OMCM), a global provider of clinical data management technology, has launched TrialOne Express, (T1xpress), a prefab eClinical solution for Phase I clinic automation.
T1xpress provides preset configurations that will enable researchers with limited resources to automate their facilities and quickly launch clinical studies. These features include a preconfigured library, barcoded label templates, preset system roles and recruitment screens.
Additionally, T1xpress also provides data capture, sample tracking, data exporting and Exago custom reporting hosted in the OmniCloud. OmniComm will offer three locations for hosting support, with regional offices in the U.S., Europe and China. The package also includes standard process workflow diagrams, a validation starter kit and a “quick-start” implementation schedule.
“OmniComm’s TrialOne solution has been widely recognized as the most functionally robust Phase I clinic automation solution in the industry,” said Stephen Johnson, president and CEO of OmniComm. “However, the level of effort to implement such a robust solution and the hardware requirements necessary to host it have, in some cases, put it out of reach for some smaller Phase I clinics. This new prepackaged and fully hosted turnkey solution will allow for a much shorter implementation schedule, affording these smaller clinics all the benefits of a tier I solution at a much lower total cost of ownership.”
Please visit www.omnicomm.com for more information
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
